New hemophilia drug aims to outperform current standard
NCT ID NCT07416604
Summary
This study is testing whether a new preventive drug called NXT007 works better than the current standard treatment, emicizumab, at reducing bleeding episodes in people with hemophilia A. It will involve 360 participants aged 12 and older who have moderate to severe hemophilia, with or without inhibitors. The main goal is to see which treatment leads to fewer bleeds requiring medication over the study period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.